In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

Humira net revenues decreased 48.7% on an operational basis to $1.682 billion, Skyrizi net revenues rose 57.9% to $3.778 billion, and Rinvoq revenues gained 47.1% to $1.834 billion. “We are ...

as its newer immunology drugs delivered growth needed to offset declining sales of its blockbuster Humira. The stock is on track for its biggest one-day percentage increase since March 26 ...

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking better each quarter for the Illinois drugmaker. On Friday ...

There are a significant number of words, phrases and acronyms that appear when talking about race and ethnicity which often change depending on the context of the conversation. Language is ...

In terms of how Stelara’s loss of exclusivity is likely to play out, “we’ve talked about the Humira erosion curve being probably the best thing to model,” Jennifer Taubert, J&J’s ...

While there are already a number of biosimilars of AbbVie's big-selling Humira on the US market, so far, only one – Boehringer Ingelheim's Cyltezo – is interchangeable with the original ...

Once Humira biosimilars entered the US markets in 2023, drug revenues declined by 32% for AbbVie. Image credit: Skorzewiak / Shutterstock AbbVie executives say the company’s immunology drugs Skyrizi ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of exclusivity (LOE) for its blockbuster drug Humira while simultaneously ...